- AGC Biologics appoints Alberto Santagostino as CEO and President, emphasizing a “friendly” and “expert” CDMO approach.
- Santagostino brings extensive biopharma experience, including leadership roles in cell and gene therapy manufacturing at Lonza.

AGC Biologics has named Alberto Santagostino as its new Chief Executive Officer and President, marking a shift toward becoming what it calls “Your friendly CDMO expert.” Santagostino, who steps into the role with two decades of biopharma industry experience, brings a clear vision of client-centered service and scaled growth within the contract manufacturing space.
Santagostino’s previous tenure includes six years leading the Cell and Gene Technology Business Unit at Lonza, where he successfully transformed cell and gene therapy manufacturing from a niche operation to industrial-scale, compliant production. During his leadership, three manufacturing sites were licensed for commercial supply, and several gene therapy products reached the market. His background also includes a role as Partner at McKinsey & Co., advising over 70 clients and developing benchmarks that continue to guide biomanufacturing performance.
“We share the common vision of service, delivery, and quality that is at the core of AGC Group’s business philosophy,” stated Tadashi Murano, President of AGC Life Science Company. “Alberto will enhance AGC Biologics’ reputation as an increasingly preferable CDMO in the industry.”
Santagostino outlined his commitment to the company’s evolving direction, stating, “We will have customers at the heart of our action and our technical talent as the enabler of our CDMO aspiration of friendly & expert services to the biopharma industry.” With this new leadership, AGC Biologics aims to strengthen its reputation as a trusted CDMO partner by focusing on accessible, supportive relationships and reliable, globally-compliant services for biopharma clients.